A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system
F Costacurta, A Dodaro, D Bante, H Schöppe… - PLoS …, 2024 - journals.plos.org
Nirmatrelvir was the first protease inhibitor specifically developed against the SARS-CoV-2
main protease (3CLpro/Mpro) and licensed for clinical use. As SARS-CoV-2 continues to
spread, variants resistant to nirmatrelvir and other currently available treatments are likely to
arise. This study aimed to identify and characterize mutations that confer resistance to
nirmatrelvir. To safely generate Mpro resistance mutations, we passaged a previously
developed, chimeric vesicular stomatitis virus (VSV-Mpro) with increasing, yet suboptimal …
main protease (3CLpro/Mpro) and licensed for clinical use. As SARS-CoV-2 continues to
spread, variants resistant to nirmatrelvir and other currently available treatments are likely to
arise. This study aimed to identify and characterize mutations that confer resistance to
nirmatrelvir. To safely generate Mpro resistance mutations, we passaged a previously
developed, chimeric vesicular stomatitis virus (VSV-Mpro) with increasing, yet suboptimal …
以上显示的是最相近的搜索结果。 查看全部搜索结果